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Monocarboxylate Transporter Expression Remains
Unchanged during the Development of Diabetic Retinal
Neuropathy in the Rat
Christopher J. Layton,1 Glyn Chidlow,1 Robert J. Casson,1 John P. M. Wood,1
Mark Graham,2 and Neville N. Osborne1
PURPOSE. To determine the effect of diabetes on monocarboxy-
late transporter (MCT) expression in the rat retina.
METHODS. Diabetes was induced in Wistar rats by a single
intraperitoneal injection of streptozotocin (62.5 mg/kg). Rats
were killed after 10 weeks, and the retinal levels of PKC,
bFGF, glial fibrillary acidic protein (GFAP), caspase-3, and
MCT1, -2, and -4 were assessed with immunoblot analysis and
RT-PCR. Hippocampal samples were used as a comparison. In
other animals, the retinas were processed histologically and
sections stained for the breakdown of DNA (TUNEL proce-
dure) and for the distribution of MCT1, -2, and -4.
RESULTS. Diabetic rats exhibited cataract formation, elevated
blood glucose levels, and polydipsia. Retinal levels and distri-
bution of MCT1, 2, and -4 were similar in the diabetic and
age-matched control groups; however, the early retinopathy
markers bFGF and PKC were significantly elevated in the
diabetic retinas but not in the hippocampal samples. ERG
recordings showed decreased oscillatory potentials in the dia-
betic group, and TUNEL staining was most evident in the
photoreceptor layer. Activated caspase-3 levels were elevated
in the diabetic retina.
CONCLUSIONS. The expression of retinal MCT1, -2, and -4 is
unaffected after 10 weeks of diabetes in rats. It appears un-
likely that diabetic retinal neuropathy is a result of a hypergly-
cemic induction of altered MCT expression. (Invest Ophthal-
mol Vis Sci. 2005;46:2878–2885) DOI:10.1167/iovs.04-1458
Diabetic retinopathy has traditionally been considered amicrovascular disease of the retina caused by excessive
tissue glucose. However, recent work has shown that neuronal
death in the retina predates the onset of microvascular changes
by many years1 and is not accompanied by similar changes in
brain tissue. Decreased retinal function can be demonstrated
early in diabetes by a loss of contrast sensitivity2 and tritan
changes in color vision that correlate with a selective loss of
S-type cones.3 Oscillatory potentials (representing the function
of the inner retina) are reduced on the electroretinogram
(ERG) in early diabetes, and this decrease predicts deteriora-
tion caused by the disease in humans.4 In humans and animal
models, there is a matching increase in apoptotic activity in the
diabetic retina, demonstrated by increased levels of activated
caspases5,6 and TUNEL staining7 and a decreased thickness of
the ganglion cell and inner plexiform layers in retinal sections.7
It has been proposed that diabetic retinal neuropathy is due
either to secondary changes in the extracellular fluid after
blood–retina barrier breakdown or to a direct effect of diabetes
on neuronal metabolism.8 The hyperglycemic changes in the
diabetic retina are thought to lead to an oversupply of glucose
in the retinal tissues and compensatory changes in other me-
tabolites, with conflicting reports concerning changes in lac-
tate, with in vivo investigations reporting both increases9,10
and decreases (Ambrosio AF, et al. IOVS 2004;45:ARVO E-Ab-
stract 3222) in the metabolite.
It is widely accepted that central nervous system (CNS)
neurons rely on glucose to maintain metabolism, but several
studies have shown that lactate, a product of the glycolytic
pathway, acts as an energy source for rat brain neurons and
astroglia in vitro.11 Lactate can support synaptic function in the
hippocampal slice12 and appears to be necessary for recovery
of this preparation from hypoxia.13 Glia release lactate under
conditions of hypoxia or hypoglycemia,14 and lactate release
has also been demonstrated in conscious rats in response to a
variety of metabolic insults.15 This finding has lead to the
suggestion that a “lactate shuttle” operates in the CNS, where
lactate is released by glia for use by neurons in a variety of
conditions.16,17 Lactate therefore appears to be an important
contributor to neural health and resistance to injury.
In the retina, the role of lactate is more controversial, with
some investigators recently presenting work consistent with
the notion that lactate is present in this tissue merely as a
byproduct of metabolism.18 However, lactate production is
known to be significantly higher in the retina than in the
brain,19 and other investigators have shown that lactate assists
in the maintenance of interactions between Mu¨ller cells, neu-
rons, and photoreceptors.20,21 Mu¨ller cells release lactate for
metabolism by photoreceptors22 and, in conditions of low
glucose, by other retinal neurons.23 It is a preferred substrate
for the Krebs cycle in photoreceptors under conditions of
intense activity19 and in protecting the optic nerve from in-
jury.24 These data, together with the previously mentioned
studies in other CNS tissue, suggest that lactate may also play
an important role in maintaining retinal health.
Lactate is transported in and out of cells by proton-coupled
monocarboxylate transporters (MCTs). Eight isoforms have
been described; with MCT1, -2, and -4 present in the retina.25
The regulation of these transporters is known to be an active
process, and alterations have been reported in the brain during
ischemia26 and diet-induced ketosis,27 two conditions known
to be characteristic of chronic uncontrolled type 1 diabetes in
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the retina.28 In the retina, inhibiting MCTs alters the ERG and
retinal metabolism.29 Given these facts and the importance of
glucose and lactate in neural metabolism, the main purpose of
this study was to elucidate whether the altered loads of glucose
and lactate present in diabetic retinal tissues alter the expres-
sion of these transporters, since any changes could contribute
to diabetic retinal neuropathy by further altering the availabil-
ity of energy substrates for neuronal metabolism.
METHODS
Animals
All experiments conformed to Principles of Laboratory Animal Care
(NIH Publication 85-23) and adhered to the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research. Twenty-eight
age-matched adult male Wistar rats (300–350 g) were housed in a
temperature- and humidity-controlled room with a 1-hour light–dark
cycle and were provided with food and water ad libitum. Rats were
randomly assigned to diabetic and control groups of 14 rats each.
Baseline random blood glucose concentrations were measured with a
glucometer (Precision PCx; Medisense, Cambridge, UK). Randomly
selected rats received an intraperitoneal injection of 62.5 mg/kg of
streptozotocin in 10 mM citrate buffer, and the control group received
an intraperitoneal injection of the citrate buffer alone and were then
left untreated until the end of the experiment. Diabetes was allowed to
continue for 10 weeks, to allow previously reported signs of diabetic
retinal neuropathy to develop.30,31 Rats were then killed and whole
retina and hippocampal samples taken for analysis.
Western Blot Analysis
Retinal proteins were isolated simultaneously with RNA (Tri-Reagent;
Sigma-Aldrich, Poole, UK). After processing, samples were solubilized
in buffer with protease inhibitors (20 mM Tris-HCl [pH 7.4], containing
2 mM EDTA, 0.5 mM EGTA, 1% SDS, 0.1 mM phenylmethylsulfonyl
fluoride, 50 g/mL aprotinin, 50 g/mL leupeptin, and 50 g/mL
pepstatin A). An equal volume of sample buffer (62.5 mM Tris-HCl [pH
7.4] containing 4% SDS, 10% glycerol, 10% -mercaptoethanol, and
0.002% bromophenol blue) was then added. Electrophoresis of sam-
ples was performed with 10% polyacrylamide gels, containing 0.1%
SDS, and the proteins were blotted onto activated ECL paper (GE
Healthcare, Little Chalfont, UK). Blots were incubated for 3 hours at
room temperature with primary antibodies against actin (monoclonal
antibody, 1:1,000; Chemicon, Chandler’s Ford, UK), MCT1 (polyclonal
anti-rabbit 1:10,000; Chemicon), MCT2 (polyclonal chicken, 1:1,000;
Chemicon UK), MCT4 (1:100 polyclonal goat; Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), bFGF (polyclonal rabbit, 1:200; Santa Cruz Bio-
technology), glial fibrillary acidic protein (GFAP; polyclonal rabbit,
1:400; Dako, Ely, UK), and activated caspase 3 (monoclonal antibody,
1:500; BD Biosciences, Cowley, UK). Blots were then incubated with
appropriate secondary antibodies conjugated to horseradish peroxi-
dase (1:5000, Sigma-Aldrich). Proteins were visualized by adding the
chemiluminescent reagent (ECL; GE Healthcare) to the blots for 1
minute, and the intensity of the fluorescence recorded on high-sensi-
tivity ECL film (GE Healthcare). The resultant bands’ intensity was
quantified by computer (LabWorks software; UVP, Inc., Upland, CA).
Semiquantitative PCR
The levels of cyclophilin; MCT1, -2, and -4; bFGF; and GFAP were
determined by semiquantitative RT-PCR, as described previously.32
Primer sequences are listed in Table 1. Briefly, total RNA was isolated
and first-strand cDNA synthesis performed on 2 g of DNase treated
RNA. Aliquots of the resultant cDNA species were amplified in PCR
buffer with MgCl2 (4 mM with MCT1, MCT2, bFGF, and GFAP and 4.5
mM with MCT4). Reactions were initiated by incubating at 94°C for 10
minutes, and PCRs (94°C, 15 seconds; 52°C, 30 seconds; 72°C, 30
seconds) were performed for a suitable number of cycles followed by
a final extension at 72°C for 3 minutes. Amplifications of each cDNA
species were performed in a single run to reduce variation. PCR
reaction products were separated on 1.5% agarose gels using ethidium
bromide for visualization. The relative abundance of each PCR product
was determined by quantitative analysis of digital photographs of the
gels viewed under UV light (LabWorks software; UVP, Inc.).
Real-Time PCR
Real-time RT-PCR reactions were performed in 96-well optical reaction
plates using the cDNA equivalent of 50 ng total RNA for each sample
in a total volume of 25 L (TaqMan Universal PCR Master Mix; Applied
Biosystems, Inc. [ABI], Foster City, CA). The thermal cycling conditions
of PCR were as follows: 50°C for 2 minutes and 95°C for 10 minutes
and 40 cycles of amplification comprising 95°C for 15 seconds and
60°C for 1 minute. The PCR assay was performed with a sequence
detector (Prism 7700; ABI). MCT primers and probes (Table 2) were
selected from GenBank (http://www.ncbi.nlm.nih.gov/genbank; pro-
vided in the public domain by the National Center for Biotechnology
TABLE 1. Sequences for Amplified mRNAs
mRNA Primer Sequences
Product Size
(bp)
Annealing Temp.
(°C) Cycles
Accession
Number
Cyclophilin 5-TGG TCA ACC CCA CCG TGT TCT TCG-3 314 bp 52 26 M19533
5-TCC AGC ATT TGC CAT GGA CAA GA-3
MCT 1 5-AGA AGT CAG CCT TCC TCC TTT-3 394 bp 55 32 D63834
5-CCA CAA GCC CAG TAT GTG TAT-3
MCT 2 5-GGC CTT CGG TAG GAT TAA TAG-3 367 bp 55 34 X97445
5-ATG CCT GAT GAT AAC ACG ACT-3
MCT 4 5-TGC GGC CCT ACT CTG TCT AC-3 369 bp 55 34 U87627
5-TCT TCC CGA TGC AGA AGA AG-3
bFGF 5-GCCTTCCCACCCGGCCACTTCAAG G-3 179 bp 55 27 M22427
5-GCACACACTCCCTTGATGGACACAA-3
GFAP 5-ATT CCG CGC CTC TCC CTG TCT C-3 437 bp 55 27 U03700
5-GCT TCA TCC GCC TCC TGT CTG T-3
TABLE 2. Effect of Experimental Diabetes on the Total Retinal Levels
of MCT1, -2, and -4 mRNAs by Real-Time PCR Relative to
Control Rats
Treatment MCT1 MCT2 MCT4
Control 1.00 (0.93–1.08) 1.00 (0.81–1.23) 1.00 (0.88–1.14)
Diabetic 0.90 (0.83–0.98) 1.04 (0.89–1.22) 1.00 (0.88–1.13)
All values are normalized to the level expressed in control rats.
Student’s unpaired t-test showed no significant differences. n 20–21.
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Information, Bethesda, MD) and designed with primer design software
(Primer Express; Applied Biosystems), whereas GAPDH primers and
probe were obtained from rodent GAPDH control reagents (TaqMan;
ABI). Amplification of GAPDH mRNA was performed as the internal
control gene, to account for variations in RNA levels between different
samples. To allow a comparison to be made between the levels of
expression of the different MCT isoforms in the retinas of control and
diabetic rats, results obtained from the real-time PCR experiments
were quantified by using the comparative threshold (2CT)
method.33 This method essentially comprises two steps: First, the
amount of target gene (MCT) in the retina is normalized to the levels
of an endogenous housekeeping gene (GAPDH), and second, the
normalized amount of target gene in diabetic retinas is expressed
relative to the normalized amount of target gene in the control retinas.
The threshold cycles (CT) were calculated on computer (Prism 7000
SDS Software; ABI).
Immunohistochemistry
Retinas were taken from rats and fixed in 4% paraformaldehyde for 30
minutes and cryopreserved in 10-m-thick frozen sections. Sections
were incubated at 4°C overnight with primary antibody against MCT1
(polyclonal rabbit, 1:1000), MCT2 (polyclonal chicken, 1:200), and
MCT 4 (polyclonal goat, 1:100). Protein was visualized with the sensi-
tive avidin-biotin-peroxidase complex kit, according to the manufac-
turer’s documentation, with the appropriate secondary antibody, 3,3-
diaminobenzidine, and 0.1% hydrogen peroxide used as substrates.
Assessment of DNA Breakdown by the
TUNEL Method
TUNEL was performed as described previously.34 Briefly, free DNA
ends were labeled in retinal sections by incubating in buffer (30-mM
Tris-HCl [pH 7.2], containing 140-mM sodium cacodylate and 1-mM
cobalt chloride) along with 0.25 U/L of terminal deoxynucleotidyl
transferase (Promega, Southampton, UK) and 10 M biotin-16-dUTP
(Roche Diagnostics, Lewes, UK). The reaction was stopped by two
15-minute washes in saline sodium citrate buffer (30 mM sodium
citrate with 300 mM sodium chloride). After an additional 15-minute
wash in 1% bovine serum albumin in phosphate-buffered saline solu-
tion, stained nuclei were visualized with CY-3 labeled streptavidin
(Fluorolink; GE Healthcare). Stained nuclei were quantified and aver-
aged for each retinal section for normal and diabetic groups.
ERG Methodology
Maximum amplitude responses from Wistar rats were recorded after
dark adaptation for at least 2 hours and preparation under dim red
illumination. Anesthesia was achieved with a dose of 0.063 mg/kg
fentanyl, 2 mg/kg fluanisone, and 1 mg/kg diazepam, and the pupils
were dilated with cyclopentolate (1%). After instillation of a single
drop of 0.4% benoxinate, the eyelids were separated by placing a
cotton thread loosely around the equator of the globe, and the rat was
placed on a stereotactic frame facing the stimulus at a distance of 50
cm. A reference electrode was placed through the ear, a grounding
electrode was attached to the scruff of the neck, and a platinum
electrode was placed in contact with the central cornea. The cornea
was intermittently irrigated with physiologic saline (BSS; Alcon, Fort
Worth, TX), to maintain the baseline recording and to prevent expo-
sure keratopathy. All recordings were made in near darkness, and the
rats were kept warm during and after the procedure.
After a single flash, responses to four subsequent flashes (10 s, 0.1
Hz) from a photic stimulator (Grass PS33-plus; Grass-Telefactor, Instru-
ment Division, West Warwick, RI) set at maximum brightness (setting
16, 17.5 cd-s/m2) were amplified (gain set at 300), filtered (100-Hz
low-pass filter, DC high-pass filter, and 50-Hz filter notch activated) and
averaged (1902 Signal Conditioner/1401 Laboratory Interface; CED,
Cambridge, UK) to give the maximum ERG response. The b-wave
amplitude was measured from the trough of the a-wave to the peak of
the b-wave, and the a-wave was measured as the difference in ampli-
tude between the recording at onset and the trough of the negative
deflection. Oscillatory potentials were obtained by treating recordings
with a digital band-pass filter between 60 and 200 Hz and total oscil-
latory potentials measured from trough to adjacent peak of the four
largest potentials. Recordings were taken 9 weeks after the adminis-
tration of streptozotocin, 1 week before sample collection.
Statistical Analysis
Analysis was performed on computer (SPSS statistical package, ver. 11;
SPSS Science, Chicago, IL). Animal weights and blood glucose levels
were compared by using Student’s unpaired t-test and the Mann-
Whitney test. Both produced similar results. mRNA and protein ex-
pression in the retina and hippocampus was analyzed with the aid of
the Oxford University Department of Statistics, using both samples
from each animal and the repeated-measures function of the analysis
software (SPSS) to allow for intra- and interanimal variability. All results
are given as the mean  SEM. P  0.05 was considered significant.
RESULTS
Confirmation of Experimental Diabetes
Before induction of diabetes, there was no significant differ-
ence between control and diabetic animals’ weights or random
blood glucose levels. No rats had obvious cataract at the be-
ginning of the experiment. Ten weeks after injection of strep-
tozotocin, the random blood glucose concentration in the
diabetic and control group was 31.4  0.9 and 8.2  0.3 mM,
respectively (P  0.001). Ten of the 14 diabetic rats were
noted to have cataracts, and the water intake of diabetic groups
was markedly increased. Although slightly heavier at the be-
ginning of the experiment due to the randomization process,
the diabetic group did not gain weight at any time during the
experimental period (Fig. 1), with final weights of 340.0 
24.6 g compared with 482  28.5 g in the control group (P 
0.001).
FIGURE 1. Serial weight measurements in the diabetic and control
groups. Rats were weighed fortnightly from the time diabetes was
confirmed, with random blood glucose measurement. Error bars are 
SEM. Statistically significant differences in the weights of the groups
relative to baseline measurements were evident after 4 weeks of
diabetes. P  0.05 by Student’s t-test with 14 animals in each group.
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Changes in MCT Expression in
Experimental Diabetes
Figure 2 shows that levels of MCT mRNA and protein were
not significantly changed in the diabetic retina. Hippocam-
pal samples also showed no change in the levels of these
transporters in diabetes. These results were supported by
the real-time PCR technique, which showed no changes in
mRNA expression of MCTs (Table 2). The close correlation
between the methods supports results of previous work
showing that semiquantitative PCR has a precision similar to
that of real-time PCR in the analysis of whole retinal ly-
sates.35 Immunohistochemistry supports this finding (Fig.
3). No obvious change in the intensity or distribution of
MCT1, -2, or -4 was evident in sections of control or diabetic
retina taken at similar eccentricities.
Markers of Retinopathy and Neuropathy
Protein and mRNA levels of both bFGF and GFAP (Fig. 4) were
elevated in the diabetic groups compared with the control
animals. Protein levels of PKC increased significantly in the
FIGURE 2. MCT expression in the retina. (A) mRNA levels in the retina by semiquantitative PCR. (B) Protein levels in the retina. (C) mRNA levels
in the hippocampus by semiquantitative PCR. (D) Protein levels in the hippocampus. Probabilities reflect significance differences, allowing for
intraclass correlation between the eyes, with 20 eyes in each group.
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experimental groups, and activated caspase-3 levels were also
elevated in diabetes (Fig. 4), but levels of both substances were
unchanged in the hippocampus (results not shown). Cells
staining prominently for TUNEL were very few in number,
with the most evident TUNEL staining in the photoreceptor
layer (Fig. 5). Some very weakly stained TUNEL cells appeared
also in the inner retinal layers of diabetic animals (Fig. 5). In
addition, ERG measurements showed significant reduction in
oscillatory potentials, a measure of inner retinal function, in
the diabetic rats (P  0.001). The b-wave amplitude was also
reduced, probably representing a loss of the oscillatory poten-
tials at the peak of the b-wave, but the change was not signif-
icant (P  0.1), and the a-wave amplitude was unchanged,
indicating that cataract did not reduce the amount of light
FIGURE 3. Immunohistochemistry
showing MCT1, -2, and -4 distribu-
tion in the retina in control and dia-
betic rats. (A) MCT1 retinal distribu-
tion in a control eye. (B) MCT1
distribution in diabetes. In both reti-
nas, MCT1 was localized in the RPE,
inner segments of the photorecep-
tors, and the outer nuclear layer.
Some staining was noted in the inner
plexiform layer. (C) MCT2 retinal dis-
tribution in the control eye. (D)
MCT2 retinal distribution in the dia-
betic eye. In both retinas, MCT2 was
localized in the plexiform layers and
the inner limiting membrane. (E)
MCT4 expression in the control eye.
(F) MCT4 expression in the diabetic
eye. In both retinas, MCT4 was local-
ized in the plexiform layers and the
nerve fiber layer. (G) Retinal section
incubated with no primary antibody
and polyclonal rabbit, chicken, and
goat. No background staining was
noted. 1, retinal pigment epithelium;
2, photoreceptor layer; 3, outer nu-
clear layer; 4, outer plexiform layer;
5, inner nuclear layer; 6, inner plex-
iform layer; 7, ganglion cell layer; 8,
nerve fiber layer/inner limiting mem-
brane. Magnification, 180.
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reaching the retina sufficiently to produce a submaximum
response (Fig. 6).
DISCUSSION
In this investigation, neither MCT proteins or mRNA levels in
the retina were significantly affected in the diabetic group. This
was somewhat surprising, because MCT1 has been shown to
be altered in the brain within hours by ischemia26 and after 6
weeks in diet induced-ketosis,27 both of which conditions
reflect some aspects of the diabetic process in the retina. In
addition, it was also recently reported that lactate levels are
decreased in the diabetic retina (Ambrosio AF, et al. IOVS
2004;45:ARVO E-Abstract 3222). It is possible that changes
caused by these factors were altered by other manifestations
associated with diabetes but absent in models of ischemia or
ketosis (for example, elevated glucose) which may produce
counterregulatory influences on the transcription and transla-
tion of the MCTs. In this study, rats were kept diabetic for 10
weeks to allow the development of diabetic retinal neuropathy
described by other investigators,31 and it is possible that MCTs
were altered earlier in this model and were normalized by the
10-week endpoint. However the lack of change in MCT ex-
pression in the retina in diabetes reflects findings from previ-
ous work in diabetic muscle.36 These findings do not rule out
the possibility that a retinal failure in MCT regulation contrib-
utes to retinal damage. However, this possibility is less likely,
given the findings in the hippocampal sections, where similar
expression profiles were found.
The rats in the diabetic group displayed the classic signs of
polyuria, polydipsia, and cataract at the end of the experiment.
Blood glucose elevations were significant, and consistently
elevated blood glucose concentrations were noted over the 10
weeks. In addition, the rats showed elevations in bFGF, PKC,
and GFAP in the retina. bFGF, an important factor associated
with CNS injury and angiogenesis, is thought to be a causative
factor in the progression of proliferative diabetic retinopa-
thy,37 but it also exhibits potent neuroprotective properties.38
It has been suggested that its release in diabetes is a response
to diabetic retinal insult,1 and work in our laboratory supports
this finding (Layton CJ, unpublished data, 2004). PKC is a
substance involved in second-messenger signal transduction
and is heavily expressed in rod bipolar cells and characteristi-
cally upregulated in the diabetic retina. In diabetes, it both
induces and is induced by angiogenic substances such as vas-
cular endothelial growth factor (VEGF),39 and the changes
shown in the current study may therefore indicate a change in
rod bipolar function in diabetes. GFAP is a marker of glial cell
activation that appears between 2 and 6 months after the onset
of diabetes and has been used by other investigators as an
endpoint in evaluating treatments of diabetic retinopathy.40
Together, these three findings indicate that the diabetic pro-
cess was well established in the retina at a point when the MCT
levels seemed stable.
The evidence presented herein also shows that previously
reported signs of diabetic retinal neuropathy were evident in
the experimental group after 10 weeks of the disease. ERG
recordings demonstrated a significant decrease in oscillatory
potentials, traditionally interpreted as a functional impairment
in the inner retina. The slight but clear increase in the number
of TUNEL-stained cells in our retinal sections, consistent with
results of the work of other investigators, showed most of the
apoptotic cells in the photoreceptor layer, as has also been
reported by Park et al.41 Clear staining of TUNEL-positive cells
in the inner retina or blood vessels as previously reported in
other investigations involving human tissue7 was not con-
firmed. Although the apoptotic activity in the retina noted in
this study was subtle, together these results show both inner
and outer retina to be affected at this stage of diabetes. Unfor-
tunately, TUNEL staining indicates early apoptotic changes in
localized cells and does not represent conclusive proof of
retina-wide neural disease. Therefore, the demonstration of
elevated levels of activated caspase 3 in whole retinal samples
is perhaps more significant. Caspase 3 is an “executioner”
caspase, activated only late in the apoptotic cascade, and the
observed elevations show that cell death processes are ad-
vanced after 10 weeks of experimental diabetes. This demon-
FIGURE 4. Markers of pathologic processes in the diabetic retina. (A)
mRNA markers of diabetic processes in the eye. (B) Protein markers of
diabetic processes in the eye. Probabilities represent significance dif-
ferences after accounting for intra- and interclass correlation within
animals and within groups, with 28 eyes in each group.
IOVS, August 2005, Vol. 46, No. 8 MCT Expression in the Diabetic Retina 2883
Downloaded From: http://iovs.arvojournals.org/pdfaccess.ashx?url=/data/journals/iovs/933439/ on 02/09/2017
strates an earlier increase in caspase-3 than shown previously
by other workers, who have found that, although caspase 2
and 6 were elevated after 8 weeks of diabetes, activated
caspase 3 did not increased in diabetic retinas until after 6
months.5 This discrepancy may be due to the larger sample size
in the present study, but is more likely a reflection of the
different dose of streptozotocin used in this study and the
subsequently accelerated diabetic response.
Diabetes is a chronic condition in humans, and perhaps
MCT levels are altered later in the disease. However, in this
study, retinal disease is well established before any effect on
MCT levels can be discerned. This does not rule out the
possibility that a lack of compensatory MCT changes in the
retina in response to an important diabetic stressor contributes
to diabetic retinopathy, but this possibility is reduced by the
finding that MCT levels are also unaffected in the diabetic
hippocampus, where signs of retinopathy do not occur. These
results therefore suggest it is unlikely that regulation of these
energy transporters is critical in the pathogenesis of diabetic
changes in the retina. However, it should be noted that al-
though there was no sign of altered distribution of MCTs in the
immunocytochemistry presented in the present study, subcel-
lular expression of MCTs may be altered in diabetes. Basigen
(CD147) colocalizes with MCTs and has been shown to be vital
in targeting the transporters to the cell surface42; however,
recent work by the same group showed that MCT expression
in the RPE depends on MCT gene expression and was not
modulated by CD147.43 Our results do not exclude the possi-
bility that diabetes could regulate MCT function through this
protein, altering the subcellular distribution of the transporters
and causing subtle changes that are not detectable by the
methodology used in this study. It is also possible that other,
unknown lactate transporters may be present in the retina and
contribute to diabetic changes or that an earlier change in MCT
levels, such as that reported after 6 weeks of ketosis in the
brain27 is a central part of the process.
The difference between streptozotocin-induced diabetes
and type-1 diabetes also should be mentioned. It is probable
that the induction of diabetes is not the sole action of strepto-
zotocin and that the agent is likely to have other effects.
Because streptozotocin obtains access to the cell via the GLUT
2 transporter, it may be toxic to other cells that express this
transporter. In the mature rat retina, only Mu¨ller cells express
GLUT 244; and, for this reason, a wide range of diabetic end-
points, produced by a variety of retinal cell types, were used in
this investigation to confirm the development of significant
disease.
In summary, this study has shown that early retinal changes
in diabetes, including retinal neuropathy, are readily demon-
strated after 10 weeks of streptozotocin-induced diabetes in
the rat. Despite these changes, MCT levels and distribution
appear to remain constant during this period. Therefore, it is
FIGURE 5. TUNEL-stained retinas in
(A) diabetic and (B) nondiabetic
groups. Diabetic retinas displayed
6.2  1.1 TUNEL-positive cells in the
photoreceptor layer per section,
compared with 2.1  1.2 in the con-
trol retinas. P  0.01 by Student’s
t-test, with eight independent eyes in
each group and 20 sections of each
retina. Magnification, 180.
FIGURE 6. ERG oscillatory potentials in diabetic and nondiabetic
groups. Top: a representative ERG (left) and isolated oscillatory poten-
tial (right). Both scale bars represents 0.1 mV and 10 ms. Neither a
(P 0.6) or b-wave (P 0.1) amplitude was significantly altered in the
diabetic group. Bottom: quantitation of the total of four oscillatory
potentials, measured from trough to peak, demonstrating that total
oscillatory potentials were reduced after 9 weeks of experimental
diabetes. *P  0.01 after accounting for intra- and interclass variation
between eyes and within groups, with 28 eyes in each group.
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unlikely that changes in MCT expression explain the recently
noted phenomenon of diabetic retinal neuropathy.
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